A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > BUSINESS
BUSINESS
- Plavix, Diovan Rank 1st, 3rd in Japan Ethical Drugs Sales in April-June: IMS Japan
August 26, 2013
- Eisai Files Petition with US Court to Nudge DEA over Stalled Scheduling of Fycompa
August 23, 2013
- OrphanPacific to Launch Normosang, Second Ultra Orphan Drug, on Aug. 23
August 22, 2013
- Patent Cliff Hits Major Global Drug Makers, Weak Yen Weighs on Japan Sales
August 22, 2013
- Ajinomoto Obtains Approval for CCB Atelec Tab. 20
August 22, 2013
- Kowa Receives Approval for Livalo OD Tablets 4 mg in Japan
August 22, 2013
- G-CSF Biosimilars Now on the Market; a Three-way Battle Begins
August 21, 2013
- Biosimilars to a Number of Major Drugs Including Remicade and Avastin Now in Development or in Preparation for Development
August 21, 2013
- Increasing Awareness of Biosimilars to Establish Them as a New Category; Companies Forming Alliances to Build Development and Marketing System
August 21, 2013
- Zeria Obtains Exclusive Rights in Japan for Iron Deficiency Treatment Ferinject from Vifor Pharma of Switzerland
August 21, 2013
- ASKA to Roll Out Generics of Takeda Product for 1st Time
August 20, 2013
- M3 to Team Up with Yahoo Japan on Healthcare Advertising Business
August 20, 2013
- Diovan Generics Developed as AGs, “No Comment” on December Listing: Sandoz
August 20, 2013
- BMKK, AZ Join the Fray in the Domestic Diabetes Market; Will Build Their Foundation on Byetta, Bydureon
August 20, 2013
- Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
August 16, 2013
- A Record 32 Officials at Drug-related Companies Were Paid Over 100 Million Yen in FY2012; Hiroshi Mitsuhara Was Top-paid Official of a Pharmacy Chain for the 4th Year in a Row
August 16, 2013
- Swiss OKs Schizophrenia Treatment Lurasidone: DSP, Takeda
August 15, 2013
- ViiV Healthcare Wins US Regulatory Approval for Anti-HIV Drug Dolutegravir
August 15, 2013
- Generics of the Major Anticancer Drug TS-1 Launched by Just 2 Companies Due to Development Hurdles
August 15, 2013
- Eisai Paid a Total of 18.7 Billion Yen to Doctors and Medical Institutions, 1.1 Billion Yen for Research Grants
August 14, 2013
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…